Novel co-culture strategies of tumor organoids with autologous T-cells reveal clinically relevant combinations of immune-checkpoint and targeted therapies
Preprint
Abstract
Patient derived tumor organoids (PDTOs) have become relevant pre-clinical models for therapeutic modelling since they highly recapitulate patients’ response to treatment. Nevertheless, their value for immunotherapy modelling has not been fully explored. We developed a tumor processing protocol that enable the establishment of PDTOs and tumor infiltrating lymphocytes (TILs) isolation. By the optimization of functional assays, we compared the T-cells effector functions of matching PBMCs and TILs, demonstrating that PBMCs after co-culture and TILs after initial expansion display similar responses. In addition, the evaluation of cytokine production by fluorospot in combination with an image-based killing assay enable the screening of different immune-checkpoint inhibitors as well as its combination with target inhibitors. Our proof-of-concept functional assays showed the potential and versatility of PDTOs and T-cells co-culture systems for immunotherapy screening. The optimization of scalable functional assays downstream co-culture represents a significant step forward to increase the value of PDTOs as pre-clinical models for immunotherapeutic screens.Keywords
This publication has 67 references indexed in Scilit:
- PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancerCancer Letters, 2022
- Organoid technology and applications in cancer immunotherapy and precision medicineCurrent Opinion in Biotechnology, 2020
- Application of PD-1 Blockade in Cancer ImmunotherapyComputational and Structural Biotechnology Journal, 2019
- Organoid Modeling of the Tumor Immune MicroenvironmentCell, 2018
- Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in CancerCell Reports, 2018
- Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsCell, 2018
- A Living Biobank of Breast Cancer Organoids Captures Disease HeterogeneityCell, 2018
- SnapShot: Immune Checkpoint InhibitorsCancer Cell, 2017
- An emerging role for cytopathology in precision oncologyCancer Cytopathology, 2015
- Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activationCytokine, 2006